<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319711414868</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319711414868</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Raynaud’s Phenomenon</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Association of Raynaud Syndrome With Thromboangiitis Obliterans—A Meta-Analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Hartmann</surname>
<given-names>Peter</given-names>
</name>
<degrees>MSc</degrees>
<xref ref-type="aff" rid="aff1-0003319711414868">1</xref>
<xref ref-type="corresp" rid="corresp1-0003319711414868"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mohokum</surname>
<given-names>Melvin</given-names>
</name>
<degrees>MSc</degrees>
<xref ref-type="aff" rid="aff1-0003319711414868">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schlattmann</surname>
<given-names>Peter</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff2-0003319711414868">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319711414868"><label>1</label>Department of Biometry and Clinical Epidemiology, Charité Universitätsmedizin Berlin, Berlin, Germany</aff>
<aff id="aff2-0003319711414868"><label>2</label>Department of Medical Statistics, Computer Sciences and Documentation, University Hospital of Friedrich–Schiller University Jena, Jena, Germany</aff>
<author-notes>
<corresp id="corresp1-0003319711414868">Peter Hartmann, Charité Universitätsmedizin Berlin, Department of Biometry and Clinical Epidemiology, Campus Charité Mitte, Bettenhochhaus 12. Ebene, Charitéplatz 1, 10098, Berlin, Germany Email: <email>peter.hartmann@live.de</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2012</year>
</pub-date>
<volume>63</volume>
<issue>4</issue>
<fpage>315</fpage>
<lpage>319</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Thromboangiitis obliterans (TAO) has traditionally been included among the diseases associated with Raynaud syndrome (RS). The prevalence of RS in patients with TAO is not well defined. The objective of this meta-analysis is to assess the prevalence of RS in patients with TAO. A literature search was performed for the studies dealing with RS and TAO. The studies provided sufficient data to estimate the prevalence of RS in patients with TAO. A total of 8 eligible studies, contributing data on 851 patients, were included in this meta-analysis. For TAO, a pooled prevalence of 28.1% and 95% confidence interval ([CI] = 0.158, 0.423) were obtained. Statistically publication bias was not present (<italic>P</italic> = .232). Despite some heterogeneity, there is a possible indication of an association between RS and patients with TAO.</p>
</abstract>
<kwd-group>
<kwd>thromboangiitis obliterans</kwd>
<kwd>Buerger disease</kwd>
<kwd>meta-analysis</kwd>
<kwd>prevalence</kwd>
<kwd>Raynaud syndrome</kwd>
<kwd>Raynaud phenomenon</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0003319711414868">
<title>Introduction</title>
<p>Thromboangiitis obliterans (TAO) or Winiwarter Buerger disease is a primary systemic vasculitis of unknown etiology, which affects medium-sized arteries and veins mainly in the lower and upper extremities, causing multiple segmental arterial occlusions especially in young male smokers.<sup>
<xref ref-type="bibr" rid="bibr1-0003319711414868">1</xref>
</sup>
</p>
<p>One relevant disease that occurs in patients with TAO is Raynaud syndrome (RS).<sup>
<xref ref-type="bibr" rid="bibr2-0003319711414868">2</xref>
</sup> The disorder derives its name from Maurice Raynaud who described the first unambiguous case<sup>
<xref ref-type="bibr" rid="bibr3-0003319711414868">3</xref>
</sup> in 1862. Raynaud syndrome is classified as primary (etiology unknown), secondary (etiology known), and suspected secondary RS (causal underlying disease suspected).<sup>
<xref ref-type="bibr" rid="bibr4-0003319711414868">4</xref>
</sup> Raynaud syndrome is characterized by a paroxysmal white–blue–red or just white and blue discoloration of the fingers and toes; the attacks are induced by cold or stress, usually, cease after no more than some minutes (average 23 minutes) but can also persist for hours.<sup>
<xref ref-type="bibr" rid="bibr4-0003319711414868">4</xref>
</sup> Episodes of RS may be accompanied by a variable degree of paresthesias and pain.<sup>
<xref ref-type="bibr" rid="bibr5-0003319711414868">5</xref>
</sup>
</p>
<p>The reported prevalence<sup>
<xref ref-type="bibr" rid="bibr2-0003319711414868">2</xref>,<xref ref-type="bibr" rid="bibr6-0003319711414868">6</xref>
</sup> of RS in patients with TAO in the literature has been variable, ranging from 0% to 66%. However, these studies are of small scale and have shown heterogeneous results. Therefore, more reliable estimates of the risks of RS in patients with TAO are needed to inform patients and careers, plan clinical services, and design clinical trials.</p>
<p>With these issues in mind, we undertook a meta-analysis of the published literature with the objective of assessing an association between TAO and RS.</p>
</sec>
<sec id="section2-0003319711414868">
<title>Materials and Methods</title>
<sec id="section3-0003319711414868">
<title>Search Strategy</title>
<p>A systematic review of the literature was conducted in August 2010 using electronic databases (PubMed, ISI Web of Knowledge) supplemented by a hand search of reference lists and review articles. We assessed publications that reported prevalence of RS in patients with TAO. The following search terms were used:<list list-type="order">
<list-item>
<p>Raynaud’s phenomenon OR Raynaud’s disease OR Raynaud’s syndrome AND Thromboangiitis obliterans</p>
</list-item>
<list-item>
<p>Raynaud’s phenomenon OR Raynaud’s disease OR Raynaud’s syndrome AND Buerger’s disease</p>
</list-item>
</list>
</p>
</sec>
<sec id="section4-0003319711414868">
<title>Inclusion Criteria</title>
<p>We looked for clinical, cohort, or case–control studies. Articles were eligible if they contained information about all patients with TAO. Additionally, the number of patients who were simultaneously diseased on RS must be reported. Ideally, there is a prevalence of RS. The studies must be published in English or German.</p>
</sec>
<sec id="section5-0003319711414868">
<title>Exclusion Criteria</title>
<p>A reason for exclusion of studies was missing information about the connection between both the illnesses and the occurrence of only one of both illnesses in the study.</p>
</sec>
<sec id="section6-0003319711414868">
<title>Study Selection</title>
<p>The review process is shown in <xref ref-type="fig" rid="fig1-0003319711414868">Figure 1</xref>
. Using our search strategy, 224 citations were retrieved. After performing limits, 96 abstracts were screened, of which 41 articles were reviewed in their full-text format. We identified 8 relevant studies that met our criteria for inclusion in the meta-analysis.</p>
<fig id="fig1-0003319711414868" position="float">
<label>Figure 1.</label>
<caption>
<p>Results of literature search strategy.</p>
</caption>
<graphic xlink:href="10.1177_0003319711414868-fig1.tif"/>
</fig>
</sec>
<sec id="section7-0003319711414868">
<title>Data Extraction</title>
<p>In all, 2 reviewers, P. H. and M. M., independently extracted data from the studies. The following parameters were recorded: author, year, total number of patients, patients with TAO (at risk), patients with TAO and RS (cases), prevalence, and country. In cases of disagreement between authors about the eligibility of studies or data extraction, consensus was reached through joint reassessment.</p>
</sec>
<sec id="section8-0003319711414868">
<title>Statistical Analysis</title>
<p>Prevalences represent the ratio of the number of patients with RS to the total of number of patients with TAO in that study. A pooled prevalence was used as a summary statistic using a double arc sinus transform with the R package meta.<sup>
<xref ref-type="bibr" rid="bibr7-0003319711414868">7</xref>
</sup>
</p>
<p>Accordingly, prevalences were used to enable a forest plot. The horizontal bars in the plots represent the range of confidence interval (CI). A 95% CI was used in the analysis. The sizes of the square boxes are proportional to the total number of patients with TAO, while the positions of square boxes show the proportion of patients with RS. The forest plot was drawn by arranging studies chronologically according to the year of publication.</p>
<p>To identify the weighted average of the study-specific prevalences, we calculated a fixed effects model unless there was heterogeneity, in which case a random effects model was used. In a fixed effects model, individual studies are weighted simply by their inverse variance, while in a random effects model, the variations are randomly distributed and the central point of this distribution is the focus on the combined effect estimate. Analysis of the heterogeneity of prevalences across studies was initially carried out using a chi-square test. The degree of heterogeneity was also quantified using <italic>I</italic>
<sup>2</sup> values. The <italic>I</italic>
<sup>2</sup> statistic describes the percentage of variation across studies that is due to heterogeneity rather than chance.<sup>
<xref ref-type="bibr" rid="bibr8-0003319711414868">8</xref><xref ref-type="bibr" rid="bibr9-0003319711414868"/>–<xref ref-type="bibr" rid="bibr10-0003319711414868">10</xref>
</sup> In this meta-analysis, the heterogeneity variance was estimated using the method of DerSimonian and Laird.<sup>
<xref ref-type="bibr" rid="bibr11-0003319711414868">11</xref>
</sup> One possible alternative to analyze heterogeneity between the studies is given by finite mixture models.<sup>
<xref ref-type="bibr" rid="bibr12-0003319711414868">12</xref>
</sup> The basic idea is to assume that the population of studies of the meta-analysis consists of several subgroups with different prevalences.</p>
<p>A Galbraith plot was used to explore publication bias. The Galbraith plot is produced by first calculating the standardized estimates by dividing each estimate by its standard error.<sup>
<xref ref-type="bibr" rid="bibr13-0003319711414868">13</xref>
</sup> We assumed that publication bias may result in an overestimation of the overall prevalence (in other words, small studies which do not show a significant association are less likely to be published). With a linear regression test, we determined publication bias statistically.<sup>
<xref ref-type="bibr" rid="bibr14-0003319711414868">14</xref>
</sup>
</p>
<p>Meta-regression allows to investigate the effect of continuous, as well as categorical covariates.<sup>
<xref ref-type="bibr" rid="bibr15-0003319711414868">15</xref>
</sup> Period of publication and latitude was investigated in our meta-regression. We used a generalized linear mixed model with logit link and binomial errors. In case of heterogeneity, we used a generalized linear mixed model with multivariate normal random effects, based on Penalized Quasi-Likelihood. Thus, in this model, we can estimate the prevalence and the odds ratio for covariates influencing the prevalence. We centered the covariate period of publication to the year of the first publication (1967).</p>
<p>R version 2.10.0, the R Foundation for Statistical Computing, was used for analysis. Additional packages used in R were meta, rmeta, and CAMAN.<sup>
<xref ref-type="bibr" rid="bibr7-0003319711414868">7</xref>,<xref ref-type="bibr" rid="bibr16-0003319711414868">16</xref>,<xref ref-type="bibr" rid="bibr17-0003319711414868">17</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section9-0003319711414868">
<title>Results</title>
<sec id="section10-0003319711414868">
<title>Characteristics of Included Studies</title>
<p>A total of 8 studies with 851 patients were included in this meta-analysis. The included studies were published from 1967 to 2008. The results of the retrieved studies are summarized in <xref ref-type="table" rid="table1-0003319711414868">Table 1</xref>
. The prevalences in our meta-analysis ranged from 0 to 0.655. Looking at <xref ref-type="table" rid="table1-0003319711414868">Table 1</xref>, we find variability between studies. Among patients with TAO, we find a group of studies that estimate a prevalence of RS between 0 and 0.1. Another group of studies show a prevalence ranging from 0.2 to 0.3. There are 3 outliers with high (0.438) and very high (0.5, 0.655) prevalences. This variability between the studies also becomes obvious when looking at a forest plot of the data, which shows the estimate prevalence together with a 95% CI (<xref ref-type="fig" rid="fig2-0003319711414868">Figure 2</xref>
).</p>
<table-wrap id="table1-0003319711414868" position="float">
<label>Table 1.</label>
<caption>
<p>Prevalence of Raynaud Syndrome in Patients With Thromboangiitis Obliterans</p>
</caption>
<graphic alternate-form-of="table1-0003319711414868" xlink:href="10.1177_0003319711414868-table1.tif"/>
<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>At Risk</th>
<th>Cases</th>
<th>Prevalence</th>
<th>Country</th>
<th>Latitude (°)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Takaro and Hines<sup>
<xref ref-type="bibr" rid="bibr6-0003319711414868">6</xref>
</sup>
</td>
<td>1967</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>United States</td>
<td>38</td>
</tr>
<tr>
<td>Hill et al<sup>
<xref ref-type="bibr" rid="bibr18-0003319711414868">18</xref>
</sup>
</td>
<td>1973</td>
<td>106</td>
<td>24</td>
<td>0.226</td>
<td>Indonesia</td>
<td>−5</td>
</tr>
<tr>
<td>Olin et al<sup>
<xref ref-type="bibr" rid="bibr19-0003319711414868">19</xref>
</sup>
</td>
<td>1990</td>
<td>112</td>
<td>49</td>
<td>0.438</td>
<td>United States</td>
<td>38</td>
</tr>
<tr>
<td>Van Damme et al<sup>
<xref ref-type="bibr" rid="bibr20-0003319711414868">20</xref>
</sup>
</td>
<td>1997</td>
<td>29</td>
<td>2</td>
<td>0.069</td>
<td>Belgium</td>
<td>50.833</td>
</tr>
<tr>
<td>Jimenez-Paredes et al<sup>
<xref ref-type="bibr" rid="bibr2-0003319711414868">2</xref>
</sup>
</td>
<td>1998</td>
<td>30</td>
<td>9</td>
<td>0.3</td>
<td>Columbia</td>
<td>4</td>
</tr>
<tr>
<td>Jimenez-Paredes et al<sup>
<xref ref-type="bibr" rid="bibr2-0003319711414868">2</xref>
</sup>
</td>
<td>1998</td>
<td>55</td>
<td>36</td>
<td>0.655</td>
<td>Columbia</td>
<td>4</td>
</tr>
<tr>
<td>Stvrtinova et al<sup>
<xref ref-type="bibr" rid="bibr1-0003319711414868">1</xref>
</sup>
</td>
<td>1999</td>
<td>22</td>
<td>11</td>
<td>0.5</td>
<td>Slovakia</td>
<td>48.667</td>
</tr>
<tr>
<td>Wysokinski et a.<sup>
<xref ref-type="bibr" rid="bibr21-0003319711414868">21</xref>
</sup>
</td>
<td>2000</td>
<td>377</td>
<td>39</td>
<td>0.103</td>
<td>Poland</td>
<td>52</td>
</tr>
<tr>
<td>Salimi et al<sup>
<xref ref-type="bibr" rid="bibr22-0003319711414868">22</xref>
</sup>
</td>
<td>2008</td>
<td>116</td>
<td>27</td>
<td>0.233</td>
<td>Ireland</td>
<td>32</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="fig2-0003319711414868" position="float">
<label>Figure 2.</label>
<caption>
<p>Forest plot of the data.</p>
</caption>
<graphic xlink:href="10.1177_0003319711414868-fig2.tif"/>
</fig>
</sec>
<sec id="section11-0003319711414868">
<title>Publication Bias</title>
<p>A Galbraith plot (<xref ref-type="fig" rid="fig3-0003319711414868">Figure 3</xref>
) demonstrated that there was asymmetry of studies for RS. In the linear regression test—the Egger’s method—a publication bias was not present. The estimate of bias (intercept) amounted 3.378 with a standard error of 2.580 (<italic>P</italic> = .232).</p>
<fig id="fig3-0003319711414868" position="float">
<label>Figure 3.</label>
<caption>
<p>Galbraith plot of the data.</p>
</caption>
<graphic xlink:href="10.1177_0003319711414868-fig3.tif"/>
</fig>
</sec>
<sec id="section12-0003319711414868">
<title>Pooled Estimates</title>
<p>The fixed effects model revealed a prevalence of 0.218 with a 95% CI (0.191, 0.246). However, the χ<sup>2</sup> test for heterogeneity is significant (124.33, <italic>df</italic> = 8; <italic>P</italic> &lt; .0001). This leads to a large value of <italic>I</italic>
<sup>2</sup> = 93.6%. Thus, a random effects model is supplied to the data. It showed an overall estimate of 0.281 with a 95% CI (0.158, 0.423). This implies that 28.1% of patients with TAO also have RS.</p>
</sec>
<sec id="section13-0003319711414868">
<title>Quantifying Heterogeneity</title>
<p>According to DerSimonian and Laird, the heterogeneity variance is 0.181. The previous analysis provided an overall estimate of prevalence. This is not particularly useful when heterogeneity is present. Thus, here we performed a mixture model analysis as outlined in “Materials and Methods” section. The results are summarized in <xref ref-type="table" rid="table2-0003319711414868">Table 2</xref>
. This model can be interpreted such that there are 4 distinct latent subgroups. One portion of the studies (0.228) estimated a prevalence equal to 0.100 among patients with TAO and RS. Another part (0.315) estimated a prevalence of 0.236. The third group estimated a prevalence of 0.438 with a weight of 0.190. Finally, the fourth group revealed a prevalence of 0.635 with a weight of 0.267. Again, there is variability between studies.</p>
<table-wrap id="table2-0003319711414868" position="float">
<label>Table 2.</label>
<caption>
<p>Mixture Model for the Heterogeneity Variance</p>
</caption>
<graphic alternate-form-of="table2-0003319711414868" xlink:href="10.1177_0003319711414868-table2.tif"/>
<table>
<thead>
<tr>
<th>Mean Prevalence</th>
<th>Mixing Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.100</td>
<td>0.228</td>
</tr>
<tr>
<td>0.236</td>
<td>0.315</td>
</tr>
<tr>
<td>0.438</td>
<td>0.190</td>
</tr>
<tr>
<td>0.635</td>
<td>0.267</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section14-0003319711414868">
<title>Meta-Regression</title>
<p>The meta-regressions were performed with the period of publication and latitude as independent variables. The results are summarized in <xref ref-type="table" rid="table3-0003319711414868">Table 3</xref>
. The estimate in the year 1967 was 0.031. Within the decade (1967-1977), the odds ratio increased from 1 (95% CI 0.957, 1.111) to 1.363 (95% CI 0.647, 2.871). However, these results are not significant (<italic>P</italic> = .455). The estimate at the latitude 0° (equator) was −0.028. Within a latitude of 10°, the odds ratio decreased from 1 (95% CI 0.935, 1.011) to 0.756 (95% CI 0.511, 1.119). However, these results were also not significant (<italic>P</italic> = .207).</p>
<table-wrap id="table3-0003319711414868" position="float">
<label>Table 3.</label>
<caption>
<p>Meta-Regression Period of Publication and Latitude</p>
</caption>
<graphic alternate-form-of="table3-0003319711414868" xlink:href="10.1177_0003319711414868-table3.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Estimate</th>
<th>Standard Error</th>
<th>Odds Ratio</th>
<th>95% Confidence Interval</th>
<th>Heterogeneity Variance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year 1967</td>
<td>0.031</td>
<td>0.038</td>
<td>1.363<sup>
<xref ref-type="table-fn" rid="table-fn1-0003319711414868">
a
</xref>
</sup>
</td>
<td>0.647, 2.871</td>
<td rowspan="2">0.646</td>
</tr>
<tr>
<td>Latitude</td>
<td>−0.028</td>
<td>0.020</td>
<td>0.756<sup>
<xref ref-type="table-fn" rid="table-fn2-0003319711414868">
b
</xref>
</sup>
</td>
<td>0.511, 1.120</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319711414868">
<p>
<sup>a</sup> Odds ratio for a decade.</p>
</fn>
<fn id="table-fn2-0003319711414868">
<p>
<sup>b</sup> Odds ratio for latitude of 10°.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section15-0003319711414868">
<title>Discussion</title>
<p>The meta-analysis was performed in line with the recommendations from the Cochrane Collaboration and Quality of Reporting of meta-analysis guidelines (PRISMA).<sup>
<xref ref-type="bibr" rid="bibr23-0003319711414868">23</xref>
</sup> A quantitative analysis of the association between TAO and RS turned out to be difficult. The major obstacle was the lack of information necessary to calculate odds ratios or relative risks. The only quantitative information available allowed estimation of the prevalence of RS in patients with TAO. In this meta-analysis of the published literature between 1967 and 2008, the prevalence using the random effects model is 0.281 (95% CI 0.158, 0.423). This meta-analysis demonstrates that patients with TAO have a greater prevalence of RS than the general population. The prevalence<sup>
<xref ref-type="bibr" rid="bibr24-0003319711414868">24</xref>,<xref ref-type="bibr" rid="bibr25-0003319711414868">25</xref>
</sup> of RS in the general population is about 0.005 to 0.043. Women have higher prevalence rates as compared with men in studies reporting gender-specific prevalence.<sup>
<xref ref-type="bibr" rid="bibr5-0003319711414868">5</xref>,<xref ref-type="bibr" rid="bibr26-0003319711414868">26</xref>
</sup> This is a possible indication of an association of RS in patients with TAO.</p>
<p>The exact mechanism of RS in patients with TAO is still unclear. Van Damme et al assumed a relation between both illnesses. Moreover, extensive distal occlusive disease (eg, TAO) makes these poorly perfused extremities hypersensitive to cold (RS).<sup>
<xref ref-type="bibr" rid="bibr20-0003319711414868">20</xref>
</sup> Therefore, clinical manifestations of TAO tend to be worse during winter.<sup>
<xref ref-type="bibr" rid="bibr27-0003319711414868">27</xref>
</sup> As small blood vessels of the hands and fingers in TAO and RS change, Takaro and Hines associate both illnesses.<sup>
<xref ref-type="bibr" rid="bibr6-0003319711414868">6</xref>
</sup> Some authors describe platelet activity in RS and in TAO.<sup>
<xref ref-type="bibr" rid="bibr28-0003319711414868">28</xref>,<xref ref-type="bibr" rid="bibr29-0003319711414868">29</xref>
</sup> Smoking plays not a decisive role because it is not mentioned as a relevant factor in the etiology of RS.<sup>
<xref ref-type="bibr" rid="bibr30-0003319711414868">30</xref>
</sup> Further research of the underlying pathological mechanism in the association between TAO and RS is needed. This is a possible indication of an association between RS in patients with TAO.</p>
<p>The association between RS in patients with TAO is not likely explained by publication bias. Statistically, we did not find evidence for publication bias in the linear regression test (<italic>P</italic> = .232).</p>
<p>Not surprisingly, we found heterogeneity of the prevalence of RS in patients with TAO. The analysis of heterogeneity between studies by the finite mixture model showed 4 distinct latent subgroups. As a result, the majority estimate a moderate prevalence of 10.0% or 23.6%. On the other hand, some studies observe a high prevalence. These differences in prevalence were probably due to the lack of a precise definition for RS. Important factors that affect prevalence are an exact definition and objective diagnostic criteria.<sup>
<xref ref-type="bibr" rid="bibr31-0003319711414868">31</xref>
</sup> Another source for heterogeneity between our studies may have to do with the trends of time. There is a big difference in the publication year of the included studies, ranging from 1967 to 2008.</p>
<p>This issue in mind, we undertook a meta-regression with regard to the period of publication and latitude. Again, the results were not statistically significant. Other covariates, for example, study type or gender, were also interesting to investigate but were not particularly useful in our meta-regression because of insufficient data. In our included studies, there was only description about the total number of patients, not distinguished between women and men (gender), in general.</p>
<p>One limitation of our study is that our literature search was restricted to English and German publications. This led to a smaller number of studies. Thus, it is possible that we systematically excluded the studies published in other languages. Moreover, as there is a lot of research activity in this field, we had to make a trade-off between being strict in including only studies that were published until the end of the systematic literature research and gaining more information by including also studies that were published later.</p>
</sec>
<sec id="section16-0003319711414868">
<title>Conclusions</title>
<p>Despite some heterogeneity in the clinical studies that were performed, our meta-analysis supports the current evidence that there is a possible indication of an association between RS in patients with TAO. Climate conditions, time trend, exact definition, and objective diagnostic criteria of the prevalence of RS in patients with TAO may explain the sources of heterogeneity. Properly planned and reported cohort and case–control studies are needed in order to perform a true thorough quantitative analysis of risk factors for RS. The results of our meta-analysis of the association between RS in patients with TAO could be helpful for medical practitioners to plan and adjust clinical service.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0003319711414868">
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0003319711414868">
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319711414868">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stvrtinova</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ambrozy</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Stvrtina</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lesny</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>90 years of Buerger’s disease—what has changed?</article-title> <source>Bratisl Lek Listy</source>. <year>1999</year>;<volume>100</volume>(<issue>3</issue>):<fpage>123</fpage>–<lpage>128</lpage>.</citation>
</ref>
<ref id="bibr2-0003319711414868">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jimenez-Paredes</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Cañas-Dávila</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Sanchez</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Restrepo</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Peña</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Iglesias-Gamarra</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Buerger’s disease at the ‘San Juan De Dios' Hospital, Santa Fe De Bogota, Colombia</article-title>. <source>Int J Cardiol</source>. <year>1998</year>;<volume>66</volume>(<issue>suppl 1</issue>):<fpage>S267</fpage>–<lpage>S272</lpage>.</citation>
</ref>
<ref id="bibr3-0003319711414868">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Block</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Sequeira</surname>
<given-names>W</given-names>
</name>
</person-group>. <article-title>Raynaud’s phenomenon</article-title>. <source>Lancet</source>. <year>2001</year>;<volume>357</volume>(<issue>9273</issue>):<fpage>2042</fpage>–<lpage>2048</lpage>.</citation>
</ref>
<ref id="bibr4-0003319711414868">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heidrich</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Functional vascular diseases: Raynaud’s syndrome, acrocyanosis and erythromelalgia</article-title>. <source>Vasa</source>. <year>2010</year>;<volume>39</volume>(<issue>1</issue>):<fpage>33</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr5-0003319711414868">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fraenkel</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Raynaud’s phenomenon: epidemiology and risk factors</article-title>. <source>Curr Rheumatol Rep</source>. <year>2002</year>;<volume>4</volume>(<issue>2</issue>):<fpage>123</fpage>–<lpage>128</lpage>.</citation>
</ref>
<ref id="bibr6-0003319711414868">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takaro</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hines</surname>
<given-names>EA</given-names>
<suffix>Jr</suffix>
</name>
</person-group>. <article-title>Digital arteriography in occlusive arterial disease and clubbing of the fingers</article-title>. <source>Circulation</source>. <year>1967</year>;<volume>35</volume>(<issue>4</issue>):<fpage>682</fpage>–<lpage>689</lpage>.</citation>
</ref>
<ref id="bibr7-0003319711414868">
<label>7</label>
<citation citation-type="other">
<person-group person-group-type="author"><name><surname>Schwarzer</surname><given-names>G</given-names></name></person-group>, <collab collab-type="author">meta: meta-analysis with R [computer software]</collab>. <year>2010</year>. p. <article-title>Fixed and random effects meta-analysis. Functions for tests of bias, forest and funnel plot</article-title>.
</citation>
</ref>
<ref id="bibr8-0003319711414868">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Axford</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Gilchrist</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Propranolol in the treatment of hypertension</article-title>. <source>Br J Clin Pract</source>. <year>1971</year>;<volume>25</volume>(<issue>7</issue>):<fpage>326</fpage>–<lpage>328</lpage>.</citation>
</ref>
<ref id="bibr9-0003319711414868">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Higgins</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>SG</given-names>
</name>
</person-group>. <article-title>Quantifying heterogeneity in a meta-analysis</article-title>. <source>Stat Med</source>. <year>2002</year>;<volume>21</volume>(<issue>11</issue>):<fpage>1539</fpage>–<lpage>1558</lpage>.</citation>
</ref>
<ref id="bibr10-0003319711414868">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Higgins</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Deeks</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Altman</surname>
<given-names>DG</given-names>
</name>
</person-group>. <article-title>Measuring inconsistency in meta-analyses</article-title>. <source>BMJ</source>. <year>2003</year>;<volume>327</volume>(<issue>7414</issue>):<fpage>557</fpage>–<lpage>560</lpage>.</citation>
</ref>
<ref id="bibr11-0003319711414868">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>DerSimonian</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Laird</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Meta-analysis in clinical trials</article-title>. <source>Control Clin Trials</source>. <year>1986</year>;<volume>7</volume>(<issue>3</issue>):<fpage>177</fpage>–<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr12-0003319711414868">
<label>12</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Schlattmann</surname>
<given-names>P</given-names>
</name>
</person-group>. In: <source>Medical Applications of Finite Mixture Models</source>.<year>2009</year>;<publisher-loc>Berlin Heidelberg</publisher-loc>: <publisher-name>Springer-Verlag;</publisher-name>, </citation>
</ref>
<ref id="bibr13-0003319711414868">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galbraith</surname>
<given-names>RF</given-names>
</name>
</person-group>. <article-title>Graphical display of estimates having differing standard errors</article-title>. <source>Technometrics</source>. <year>1988</year>;<volume>30</volume>(<issue>3</issue>):<fpage>271</fpage>–<lpage>281</lpage>.</citation>
</ref>
<ref id="bibr14-0003319711414868">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Egger</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Davey Smith</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Minder</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ</source>. <year>1997</year>;<volume>315</volume>(<issue>7109</issue>):<fpage>629</fpage>–<lpage>634</lpage>.</citation>
</ref>
<ref id="bibr15-0003319711414868">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thompson</surname>
<given-names>SG</given-names>
</name>
</person-group>. <article-title>How should meta-regression analyses be undertaken and interpreted</article-title>. <source>Stat Med</source>. <year>2002</year>;<volume>21</volume>(<issue>11</issue>):<fpage>1559</fpage>–<lpage>1573</lpage>.</citation>
</ref>
<ref id="bibr16-0003319711414868">
<label>16</label>
<citation citation-type="other">
<person-group person-group-type="author"><name><surname>Lumley</surname><given-names>T</given-names></name></person-group>., <source>rmeta: Meta-analysis</source> <comment>[computer software]</comment>. <year>2009</year>.
</citation>
</ref>
<ref id="bibr17-0003319711414868">
<label>17</label>
<citation citation-type="other">
<person-group person-group-type="author"><name><surname>Schlattmann</surname><given-names>P</given-names></name></person-group>. <article-title>Finite Mixture Models and metaanalysis tools–based on C.A.MAN [computer software]</article-title>. <year>2008</year>.
</citation>
</ref>
<ref id="bibr18-0003319711414868">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hill</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Moeliono</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tumewu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Brataamadja</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tohardi</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>The Buerger syndrome in Java. A description of the clinical syndrome and some aspects of its aetiology</article-title>. <source>Br J Surg</source>. <year>1973</year>;<volume>60</volume>(<issue>8</issue>):<fpage>606</fpage>–<lpage>613</lpage>.</citation>
</ref>
<ref id="bibr19-0003319711414868">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olin</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Graor</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Ruschhaupt</surname>
<given-names>WF</given-names>
</name>
<name>
<surname>Bartholomew</surname>
<given-names>JR</given-names>
</name>
</person-group>. <article-title>The changing clinical spectrum of thromboangiitis obliterans (Buerger’s disease)</article-title>. <source>Circulation</source>. <year>1990</year>;<volume>82</volume>(<issue>5 suppl</issue>):<fpage>IV3</fpage>–<lpage>IV8</lpage>.</citation>
</ref>
<ref id="bibr20-0003319711414868">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Damme</surname>
<given-names>H</given-names>
</name>
<name>
<surname>De Leval</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Creemers</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Limet</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Thrombangiitis obliterans (Buerger’s disease): still a limb threatening disease</article-title>. <source>Acta Chir Belg</source>. <year>1997</year>;<volume>97</volume>(<issue>5</issue>):<fpage>229</fpage>–<lpage>236</lpage>.</citation>
</ref>
<ref id="bibr21-0003319711414868">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wysokinski</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Kwiatkowska</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Sapian-Raczkowska</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Czarnacki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Doskocz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kowal-Gierczak</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Sustained classic clinical spectrum of thromboangiitis obliterans (Buerger’s disease)</article-title>. <source>Angiology</source>. <year>2000</year>;<volume>51</volume>(<issue>2</issue>):<fpage>141</fpage>–<lpage>150</lpage>.</citation>
</ref>
<ref id="bibr22-0003319711414868">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salimi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tavakkoli</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Salimzadeh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ghadimi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Habibi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Masoumi</surname>
<given-names>AA</given-names>
</name>
</person-group>. <article-title>Clinical characteristics of Buerger’s disease in Iran</article-title>. <source>J Coll Physicians Surg Pak</source>. <year>2008</year>;<volume>18</volume>(<issue>8</issue>):<fpage>502</fpage>–<lpage>505</lpage>.</citation>
</ref>
<ref id="bibr23-0003319711414868">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liberati</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Altman</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Tetzlaff</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration</article-title>. <source>BMJ</source>. <year>2009</year>;<volume>339</volume>:<fpage>b2700</fpage>.</citation>
</ref>
<ref id="bibr24-0003319711414868">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weinrich</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Maricq</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Keil</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>McGregor</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Diat</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Prevalence of Raynaud phenomenon in the adult population of South Carolina</article-title>. <source>J Clin Epidemiol</source>. <year>1990</year>;<volume>43</volume>(<issue>12</issue>):<fpage>1343</fpage>–<lpage>1349</lpage>.</citation>
</ref>
<ref id="bibr25-0003319711414868">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Angelis</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Salaffi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Grassi</surname>
<given-names>W</given-names>
</name>
</person-group>. <article-title>Raynaud’s phenomenon: prevalence in an Italian population sample</article-title>. <source>Clin Rheumatol.</source>. <year>2006</year>;<volume>25</volume>(<issue>4</issue>):<fpage>506</fpage>–<lpage>510</lpage>.</citation>
</ref>
<ref id="bibr26-0003319711414868">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suter</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Murabito</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Felson</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Fraenkel</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>The incidence and natural history of Raynaud’s phenomenon in the community</article-title>. <source>Arthritis Rheum</source>. <year>2005</year>;<volume>52</volume>(<issue>4</issue>):<fpage>1259</fpage>–<lpage>1263</lpage>.</citation>
</ref>
<ref id="bibr27-0003319711414868">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joyce</surname>
<given-names>JW</given-names>
</name>
</person-group>. <article-title>Buerger’s disease (thromboangiitis obliterans)</article-title>. <source>Rheum Dis Clin North Am</source>. <year>1990</year>;<volume>16</volume>(<issue>2</issue>):<fpage>463</fpage>–<lpage>470</lpage>.</citation>
</ref>
<ref id="bibr28-0003319711414868">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carr</surname>
<given-names>ME</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Hackney</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Hines</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Heddinger</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Carr</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>EJ</given-names>
</name>
</person-group>. <article-title>Enhanced platelet force development despite drug-induced inhibition of platelet aggregation in patients with thromboangiitis obliterans—two case reports</article-title>. <source>Vasc Endovascular Surg</source>. <year>2002</year>;<volume>36</volume>(<issue>6</issue>):<fpage>473</fpage>–<lpage>480</lpage>.</citation>
</ref>
<ref id="bibr29-0003319711414868">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herrick</surname>
<given-names>AL</given-names>
</name>
</person-group>. <article-title>Pathogenesis of Raynaud’s phenomenon</article-title>. <source>Rheumatology (Oxford)</source>. <year>2005</year>;<volume>44</volume>(<issue>5</issue>):<fpage>587</fpage>–<lpage>596</lpage>.</citation>
</ref>
<ref id="bibr30-0003319711414868">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bakst</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Merola</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Franks</surname>
<given-names>AG</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Sanchez</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Raynaud’s phenomenon: pathogenesis and management</article-title>. <source>J Am Acad Dermatol</source>. <year>2008</year>;<volume>59</volume>(<issue>4</issue>):<fpage>633</fpage>–<lpage>653</lpage>.</citation>
</ref>
<ref id="bibr31-0003319711414868">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Baek</surname>
<given-names>GH</given-names>
</name>
</person-group>. <article-title>Prevalence of Raynaud’s phenomenon in patients with idiopathic carpal tunnel syndrome</article-title>. <source>J Bone Joint Surg Br</source>. <year>1999</year>;<volume>81</volume>(<issue>6</issue>):<fpage>1017</fpage>–<lpage>1019</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>